LEO Pharma Adds Internationally Recognized Dermatologist to Global Leadership Team
To lead Research and Early Development, LEO Pharma has appointed Dr. Jacob Pontoppidan Thyssen as new Executive Vice President and Chief Scientific Officer.
- To lead Research and Early Development, LEO Pharma has appointed Dr. Jacob Pontoppidan Thyssen as new Executive Vice President and Chief Scientific Officer.
- Jacob is an internationally recognized dermatologist and key opinion leader who will add his clinical experience and strong understanding of patients’ needs into LEO Pharma's drug development.
- To support these two critical pillars, LEO Pharma today announced a split of its Research and Development organization into two distinct areas, both represented in the Global Leadership Team (GLT).
- I am delighted to welcome Jacob to LEO Pharma and the Global Leadership Team and am confident that his experience will help spearhead our innovative portfolio.